Search Results for: CYB5B

11 interactions involving CYB5B - cytochrome b5 type B found:

Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Phenserine
  • Tiomolibdate ion
  • CAD106
  • Mito-4509
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Alzheimer's disease (AD)
B3GNT9 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9
  • O-linked glycosylation of mucins
C16orf70 chromosome 16 open reading frame 70
CENPT centromere protein T
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
CLN8 CLN8 transmembrane ER and ERGIC protein
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
COG8 component of oligomeric golgi complex 8
  • COPI-mediated anterograde transport
  • Intra-Golgi traffic
  • Retrograde transport at the Trans-Golgi-Network
  • Congenital disorders of glycosylation (CDG) type II
CREB3 cAMP responsive element binding protein 3
  • CREB3 factors activate genes
  • CREB3 factors activate genes
ESRP2 epithelial splicing regulatory protein 2
  • FGFR2 alternative splicing
LMNA lamin A/C
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
RPS2P45 ribosomal protein S2 pseudogene 45
SLC7A6OS solute carrier family 7 member 6 opposite strand